Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Go back to Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting| (NASDAQ: RZLT) | Delayed: 5.20 +0.18 (3.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.02 | 52 Week High | $ | |||
| Open | $5.10 | 52 Week Low | $ | |||
| Day High | $5.25 | P/E | N/A | |||
| Day Low | $5.04 | EPS | $ | |||
| Volume | 839,940 | |||||
